Non-Invasive Preimplantation Genetic Screening for Aneuploidies and Clinical Outcomes in E
Preimplantation genetic testing for aneuploidies (PGT-A) is commonly used in IVF but requires embryo biopsy and shows limited benefit in egg donation cycles. Non-invasive PGT-A (niPGTA), based on the analysis of cell-free embryonic DNA in spent culture media, offers a promising biopsy-free alternative. This prospective
| Condition(s) | IVF |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Preimplantation genetic testing for aneuploidies (PGT-A) is commonly used in IVF but requires embryo biopsy and shows limited benefit in egg donation cycles. Non-invasive PGT-A (niPGTA), based on the analysis of cell-free embryonic DNA in spent culture media, offers a promising biopsy-free alternative. This prospective, blinded study in egg donation cycles will evaluate whether niPGTA-detected aneuploidy is associated with implantation failure and pregnancy loss, assessing its potential clinical value as a non-invasive embryo selection tool. |
| Who can participate | Inclusion Criteria: * Women between 18 and 50 years old who are oocyte recipients. * Signed consent form * Transfer of a single blastocyst-stage embryo * Male with normal sperm FISH Exclusion Criteria: * Uterine malformations * Abnormal karyotypes in either partner * Failure to sign informed consent |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Instituto Bernabeu |
| Locations | Alicante, Spain |
| Start date | 2026-02-26 |
| NCT ID | NCT07364526 |
| Official listing | https://clinicaltrials.gov/study/NCT07364526 |